Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer.

Only a small number of promising drugs target pancreatic cancer, which is the fourth leading cause of cancer deaths with a 5-year survival of less than 5%. Our goal is to develop a new biotherapeutic agent in which a lysosomal protein (saposin C, SapC) and a phospholipid (dioleoylphosphatidylserine,...

Full description

Bibliographic Details
Main Authors: Zhengtao Chu, Shadi Abu-Baker, Mary B Palascak, Syed A Ahmad, Robert S Franco, Xiaoyang Qi
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3790873?pdf=render